Status:
COMPLETED
The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients
Lead Sponsor:
Farwaniya Hospital
Conditions:
Corneal Perforation
Exposure Keratitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Case series of 5 ICU patients in Farwaniya Hospital who developed exposure keratitis and a subsequent small corneal perforation between April 2022 and April 2024. The investigators highlight the non-...
Detailed Description
The primary outcome measures were healing of the corneal perforation, a negative Seidel test and reformation of the anterior chamber. Secondary outcome measures were improvement of all three of cilia...
Eligibility Criteria
Inclusion
- Inclusion/Exclusion Criteria:
- Patients with small corneal perforations measuring \< 1 mm in diameter. Those with larger perforations (\>1mm) were excluded.
- Patients with conclusive results of keratitis (confirmed via culture and sensitivity scraping) AND showing improved keratitis following antibiotic treatment. Those with no confirmed keratitis through C\&S or with inconclusive scraping results were excluded.
- No age or gender restrictions were applied.
Exclusion
Key Trial Info
Start Date :
April 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2024
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT06539663
Start Date
April 10 2022
End Date
April 10 2024
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Farwaniya Hospital
Kuwait City, Kuwait, 81004, PO Box 13372